Roivant's oral uveitis drug Lisraya succeeds in two Phase 3 trials
Start here
Roivant and its spinout Priovant reported that Lisraya, an oral immune-modulating drug, beat placebo in treating non-infectious uveitis. The results come from two Phase 3 trials enrolling 371 patients. The companies estimate 70,000 to 190,000 people in the U.S. have the condition, and more than 40,000 of them are already being treated with Humira or a similar therapy, suggesting a market for an oral alternative. Lisraya was approved for dermatomyositis in August. Roivant plans to file for U.S. approval of the uveitis indication in the first half of next year. What remains open: full trial data have not been detailed, and regulatory review has not yet begun.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- STATPickSTAT+: Roivant says closely watched immune drug succeeded in new eye disease
Roivant and its spinout Priovant said Wednesday that the oral immune-modulating drug Lisraya was more effective than placebo in treating non-infectious uveitis. Two Phase 3 trials enrolled 371 patients; the company estimates 70,000 to 190,000 U.S. patients have the condition, with over 40,000 already on Humira or a similar therapy. Roivant plans to file for approval in the first half of next year; the drug was approved for dermatomyositis in August.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 21:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.